Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer
ConditionLung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorVanderbilt-Ingram Cancer Center
About this trial
RATIONALE: Using samples of blood, urine, sputum, and lung tissue from patients at high risk of cancer for laboratory studies may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at molecular predictors of cancer in patients at high risk of lung cancer.
Eligibility criteria
Qualifiers
None
Disqualifiers
Inability to provide informed consent
Minors
Pregnant women
Trial design
Treatments tested in this trial
- comparative genomic hybridization
- gene expression microarray analysis
- proteomic profiling analysis
- biologic sample preservation procedure
- nasal brushing
- Blood draw
- Urine collection
- sputum sample
- fluorescence bronchoscopy with airway biopsy
- fine needle aspiration of the lung
- thoracentesis
Treatment groups
4,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Vanderbilt-Ingram Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov